Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00032279
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2002-03-15
Brief Title:
Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease
Sponsor:
Fred Hutchinson Cancer Center
Organization:
Facet Biotech
Study Overview
Official Title:
A Phase II Multicenter Clinical Trial Evaluating the Use of Humanized Monoclonal Anti-CD3 Antibody VisilizumabNuvion as Second-line Therapy for Glucocorticoid-Refractory Acute Graft-Versus-Host Disease
Status:
UNKNOWN
Status Verified Date:
2003-10
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this phase II study is to evaluate an investigational monoclonal antibody for the treatment of glucocorticoid-refractory Graft Versus Host Disease GVHD Patients diagnosed with GVHD who have not responded satisfactorily to or are intolerant of treatment with standard agents will be considered for entry Patients will be allowed to continue on their other immunosuppressive drugs at stable doses during the trial The research is being conducted at up to 20 clinical research sites in the US
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None